阿尼制药 ANIP 深 沪
等待开盘 03-27 09:30:00 美东时间
74.14
+0.070
+0.09%
华盛通- 最 高77.97
- 今 开73.53
- 成交量 24.11万股
- 最 低 70.15
- 昨 收 74.07
- 总市值 127.87万
- 52周最高 99.50
- 市盈率 静 --
- 换手率 1397.70%
- 52周最低 56.71
- 委 比 98.79%
- 总股本 1.72万
- 历史最高 108.72
- 量 比 0
- 振 幅 10.56%
- 历史最低 1.10
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%.
02-27 22:46
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
In a preclinical study presented at the 2025 EULAR Congress, Purified Cortrophin Gel showed efficacy in reducing joint swelling and inflammatory cytokine response in a murine collagen-induced arthritis model, without causing additional bone turnover. The study highlights its potential for treating inflammatory arthritis conditions.
2025-06-12 11:00
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
ANI Pharmaceuticals' CEO, Nikhil Lalwani, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35pm ET. The live and archived webcast will be available on the Company’s website under the Investors section.
2025-05-27 20:30
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
ANI Pharmaceuticals announced a Phase 4 clinical trial comparing two dose levels of Purified Cortrophin Gel for treating acute gout flares, evaluating safety and efficacy.
2025-05-22 10:50
ANI Pharmaceuticals Reports FDA Approval And Commercialization Of Ketoconazole Shampoo, 2%
NI's Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral. U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2 million, based on
2024-09-26 18:52
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 4 analysts in the last t...
2024-09-17 20:01
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-12 00:13
Truist Securities Downgrades ANI Pharmaceuticals to Hold, Lowers Price Target to $60
Truist Securities analyst Gregory Fraser downgrades ANI Pharmaceuticals (NASDAQ:ANIP) from Buy to Hold and lowers the price target from $80 to $60.
2024-09-11 18:47
